Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

NEC OncoImmunity Publishes a Unique HLA Typing Technology That Discovers New HLA Alleles, and Tumor Specific HLA Alleles

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide personalized cancer immunotherapy.

The computational approach performs HLA typing from next-generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI.

NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing approach from the blood of numerous donors using deep targeted HLA sequencing. The validation confirmed almost 100% of HLA typing success at the 1st and 2nd fields of resolution.

The approach was published in the peer-review journal HLA where the first author Anzar and her colleagues also demonstrated how the approach led to the discovery of a new officially named HLA allele, from standard sequencing data routinely used in the design of personalized cancer vaccines.

“This approach is an important development in the field of precision immunotherapy. It will help the HLA typing community to fill gaps in the global human HLA libraries and help identify novel HLA variants in disease association studies in addition to improving the accuracy of HLA-typing for organ transplantation and vaccine design. We will now use this unique addition to our bioinformatics toolbox to further characterize the relationship between variation in HLA alleles and response to cancer immunotherapy.” Said, Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity.

References

Title: Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants

Authors: Irantzu Anzar, Angelina Sverchkova, Pubudu Samarakoon, Espen Basmo Ellingsen, Gustav Gaudernack, Richard Stratford and Trevor Clancy

URL: https://onlinelibrary.wiley.com/doi/10.1111/tan.14562

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine